{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:23:20Z","timestamp":1782807800865,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Spanish Ministry of Economy and Competitiveness MEC","doi-asserted-by":"publisher","award":["SAF2014\u201052361\u2010R"],"award-info":[{"award-number":["SAF2014\u201052361\u2010R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Spanish Ministry of Economy and Competitiveness MEC","doi-asserted-by":"publisher","award":["SAF2017\u201383267\u2010C2\u20131\u2010R"],"award-info":[{"award-number":["SAF2017\u201383267\u2010C2\u20131\u2010R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007406","name":"Fundaci\u00f3n BBVA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007406","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2020,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Live 17D is widely used as a prophylactic vaccine strain for yellow fever virus that induces potent neutralizing humoral and cellular immunity against the wild\u2010type pathogen. 17D replicates and kills mouse and human tumor cell lines but not non\u2010transformed human cells. Intratumoral injections with viable 17D markedly delay transplanted tumor progression in a CD8 T\u2010cell\u2010dependent manner. In mice bearing bilateral tumors in which only one is intratumorally injected, contralateral therapeutic effects are observed consistent with more prominent CD8 T\u2010cell infiltrates and a treatment\u2010related reduction of Tregs. Additive efficacy effects were observed upon co\u2010treatment with intratumoral 17D and systemic anti\u2010CD137 and anti\u2010PD\u20101 immunostimulatory monoclonal antibodies. Importantly, when mice were preimmunized with 17D, intratumoral 17D treatment achieved better local and distant antitumor immunity. Such beneficial effects of prevaccination are in part explained by the potentiation of CD4 and CD8 T\u2010cell infiltration in the treated tumor. The repurposed use of a GMP\u2010grade vaccine to be given via the intratumoral route in prevaccinated patients constitutes a clinically feasible and safe immunotherapy approach.<\/jats:p>","DOI":"10.15252\/emmm.201910375","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T02:31:06Z","timestamp":1574217066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Repurposing the yellow fever vaccine for intratumoral immunotherapy"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7970-1672","authenticated-orcid":false,"given":"Maria Angela","family":"Aznar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Teijeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantza","family":"Azpilikueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saray","family":"Garasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso R","family":"Sanchez\u2010Paulete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki","family":"Etxeberria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Rius\u2010Rocabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estanislao","family":"Nistal\u2010Villan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"key":"BFEMMM201910375_CR1","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1073\/pnas.1718217115","volume":"115","author":"E Ahn","year":"2018","unstructured":"Ahn E, Araki K, Hashimoto M, Li W, Riley JL, Cheung J, Sharpe AH, Freeman GJ, Irving BA, Ahmed R (2018) Role of PD\u20101 during effector CD8 T cell differentiation. Proc Natl Acad Sci USA 115: 4749\u20134754","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM201910375_CR2","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Aga Rwala SS et\u00a0al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33: 2780\u20132788","journal-title":"J Clin Oncol"},{"key":"BFEMMM201910375_CR3","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","volume":"23","author":"RH Andtbacka","year":"2016","unstructured":"Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, Amatruda T, Zager JS, Cranmer L, Hsueh E et\u00a0al (2016) Patterns of clinical response with talimogene laherparepvec (T\u2010VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol 23: 4169\u20134177","journal-title":"Ann Surg Oncol"},{"key":"BFEMMM201910375_CR4","doi-asserted-by":"crossref","first-page":"e998538","DOI":"10.1080\/2162402X.2014.998538","volume":"4","author":"L Apetoh","year":"2015","unstructured":"Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A et\u00a0al (2015) Consensus nomenclature for CD8(+) T cell phenotypes in cancer. Oncoimmunology 4: e998538","journal-title":"Oncoimmunology"},{"key":"BFEMMM201910375_CR5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1101\/sqb.78.019869","volume":"78","author":"K Araki","year":"2013","unstructured":"Araki K, Youngblood B, Ahmed R (2013) Programmed cell death 1\u2010directed immunotherapy for enhancing T\u2010cell function. Cold Spring Harb Symp Quant Biol 78: 239\u2013247","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"BFEMMM201910375_CR6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4049\/jimmunol.1601145","volume":"198","author":"MA Aznar","year":"2017","unstructured":"Aznar MA, Tinari N, Rullan AJ, Sanchez\u2010Paulete AR, Rodriguez\u2010Ruiz ME, Melero I (2017) Intratumoral delivery of immunotherapy\u2010act locally, think globally. J Immunol 198: 31\u201339","journal-title":"J Immunol"},{"key":"BFEMMM201910375_CR7","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.4049\/jimmunol.1402605","volume":"194","author":"MR Bassi","year":"2015","unstructured":"Bassi MR, Kongsgaard M, Steffensen MA, Fenger C, Rasmussen M, Skjodt K, Finsen B, Stryhn A, Buus S, Christensen JP et\u00a0al (2015) CD8+ T cells complement antibodies in protecting against yellow fever virus. J Immunol 194: 1141\u20131153","journal-title":"J Immunol"},{"key":"BFEMMM201910375_CR8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/infdis\/jit546","volume":"209","author":"A Beck","year":"2014","unstructured":"Beck A, Tesh RB, Wood TG, Widen SG, Ryman KD, Barrett AD (2014) Comparison of the live attenuated yellow fever vaccine 17D\u2010204 strain to its virulent parental strain Asibi by deep sequencing. J Infect Dis 209: 334\u2013344","journal-title":"J Infect Dis"},{"key":"BFEMMM201910375_CR9","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1073\/pnas.0801497105","volume":"105","author":"SD Blackburn","year":"2008","unstructured":"Blackburn SD, Shin H, Freeman GJ, Wherry EJ (2008) Selective expansion of a subset of exhausted CD8 T cells by alphaPD\u2010L1 blockade. Proc Natl Acad Sci USA 105: 15016\u201315021","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM201910375_CR10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","volume":"18","author":"PK Bommareddy","year":"2018","unstructured":"Bommareddy PK, Shettigar M, Kaufman HL (2018) Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol 18: 498\u2013513","journal-title":"Nat Rev Immunol"},{"key":"BFEMMM201910375_CR11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","volume":"131","author":"C Chester","year":"2018","unstructured":"Chester C, Sanmamed MF, Wang J, Melero I (2018) Immunotherapy targeting 4\u20101BB: mechanistic rationale, clinical results, and future strategies. Blood 131: 49\u201357","journal-title":"Blood"},{"key":"BFEMMM201910375_CR12","first-page":"375","volume":"131","author":"WB Coley","year":"1906","unstructured":"Coley WB (1906) Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and bacillus prodigiosus. Am J Med Sci 131: 375\u2013430","journal-title":"Am J Med Sci"},{"key":"BFEMMM201910375_CR13","first-page":"1","volume":"3","author":"WB Coley","year":"1910","unstructured":"Coley WB (1910) The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med 3: 1\u201348","journal-title":"Proc R Soc Med"},{"key":"BFEMMM201910375_CR14","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41467-018-07195-w","volume":"9","author":"M Compte","year":"2018","unstructured":"Compte M, Harwood SL, Munoz IG, Navarro R, Zonca M, Perez\u2010Chacon G, Erce\u2010Llamazares A, Merino N, Tapia\u2010Galisteo A, Cuesta AM et\u00a0al (2018) A tumor\u2010targeted trimeric 4\u20101BB\u2010agonistic antibody induces potent anti\u2010tumor immunity without systemic toxicity. Nat Commun 9: 4809","journal-title":"Nat Commun"},{"key":"BFEMMM201910375_CR15","first-page":"eaal1713","volume":"2","author":"P Dai","year":"2017","unstructured":"Dai P, Wang W, Yang N, Serna\u2010Tamayo C, Ricca JM, Zamarin D, Shuman S, Merghoub T, Wolchok JD, Deng L (2017) Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3\u2010dependent dendritic cells. Sci\u00a0Immunol 2: eaal1713","journal-title":"Sci\u00a0Immunol"},{"key":"BFEMMM201910375_CR16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1006\/biol.1999.0239","volume":"28","author":"J Fournier\u2010Caruana","year":"2000","unstructured":"Fournier\u2010Caruana J, Poirier B, Garnier F, Fuchs F (2000) In vitro potency assay for yellow fever vaccines: comparison of three vero cell lines sources. Biologicals 28: 33\u201340","journal-title":"Biologicals"},{"key":"BFEMMM201910375_CR17","doi-asserted-by":"crossref","first-page":"282ra48","DOI":"10.1126\/scitranslmed.aaa3700","volume":"7","author":"SA Fuertes Marraco","year":"2015","unstructured":"Fuertes Marraco SA, Soneson C, Cagnon L, Gannon PO, Allard M, Abed Maillard S, Montandon N, Rufer N, Waldvogel S, Delorenzi M et\u00a0al (2015) Long\u2010lasting stem cell\u2010like memory CD8+ T cells with a naive\u2010like profile upon yellow fever vaccination. Sci Transl Med 7: 282ra48","journal-title":"Sci Transl Med"},{"key":"BFEMMM201910375_CR18","doi-asserted-by":"crossref","first-page":"e1386829","DOI":"10.1080\/2162402X.2017.1386829","volume":"6","author":"AD Garg","year":"2017","unstructured":"Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L (2017) Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 6: e1386829","journal-title":"Oncoimmunology"},{"key":"BFEMMM201910375_CR19","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1084\/jem.20082292","volume":"205","author":"D Gaucher","year":"2008","unstructured":"Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali\u2010Mouhim A, Moser JM, Mehta RS, Drake DR III, Castro E et\u00a0al (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119\u20133131","journal-title":"J Exp Med"},{"key":"BFEMMM201910375_CR20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-4939-0428-0_5","volume":"1144","author":"WF Goins","year":"2014","unstructured":"Goins WF, Huang S, Cohen JB, Glorioso JC (2014) Engineering HSV\u20101 vectors for gene therapy. Methods Mol Biol 1144: 63\u201379","journal-title":"Methods Mol Biol"},{"key":"BFEMMM201910375_CR21","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1073\/pnas.84.7.2019","volume":"84","author":"CS Hahn","year":"1987","unstructured":"Hahn CS, Dalrymple JM, Strauss JH, Rice CM (1987) Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad Sci USA 84: 2019\u20132023","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM201910375_CR22","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS et\u00a0al (2008) Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322: 1097\u20131100","journal-title":"Science"},{"key":"BFEMMM201910375_CR23","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","volume":"12","author":"JC Hu","year":"2006","unstructured":"Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I et\u00a0al (2006) A phase I study of OncoVEXGM\u2010CSF, a second\u2010generation oncolytic herpes simplex virus expressing granulocyte macrophage colony\u2010stimulating factor. Clin Cancer Res 12: 6737\u20136747","journal-title":"Clin Cancer Res"},{"key":"BFEMMM201910375_CR24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymthe.2006.02.015","volume":"14","author":"E Huarte","year":"2006","unstructured":"Huarte E, Larrea E, Hernandez\u2010Alcoceba R, Alfaro C, Murillo O, Arina A, Tirapu I, Azpilicueta A, Hervas\u2010Stubbs S, Bortolanza S et\u00a0al (2006) Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication. Mol Ther 14: 129\u2013138","journal-title":"Mol Ther"},{"key":"BFEMMM201910375_CR25","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","volume":"77","author":"H Jiang","year":"2017","unstructured":"Jiang H, Rivera\u2010Molina Y, Gomez\u2010Manzano C, Clise\u2010Dwyer K, Bover L, Vence LM, Yuan Y, Lang FF, Toniatti C, Hossain MB et\u00a0al (2017) Oncolytic adenovirus and tumor\u2010targeting immune modulatory therapy improve autologous cancer vaccination. Can Res 77: 3894\u20133907","journal-title":"Can Res"},{"key":"BFEMMM201910375_CR26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ymthe.2006.05.008","volume":"14","author":"JH Kim","year":"2006","unstructured":"Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH et\u00a0al (2006) Systemic armed oncolytic and immunologic therapy for cancer with JX\u2010594, a targeted poxvirus expressing GM\u2010CSF. Mol Ther 14: 361\u2013370","journal-title":"Mol Ther"},{"key":"BFEMMM201910375_CR27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41467-017-00324-x","volume":"8","author":"DS Kim","year":"2017","unstructured":"Kim DS, Dastidar H, Zhang C, Zemp FJ, Lau K, Ernst M, Rakic A, Sikdar S, Rajwani J, Naumenko V et\u00a0al (2017) Smac mimetics and oncolytic viruses synergize in driving anticancer T\u2010cell responses through complementary mechanisms. Nat Commun 8: 344","journal-title":"Nat Commun"},{"key":"BFEMMM201910375_CR28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1142\/9789810248543_0004","volume-title":"The Nobel Prize the first 100\u00a0years","author":"B Lemmel","year":"2001","unstructured":"Lemmel B (2001) Nomination and selection of the Nobel laureates. In The Nobel Prize the first 100\u00a0years, Wallin\u2010Levinovitz A, Ringertze N (eds), pp 25\u201328. London: Imperial College Press"},{"key":"BFEMMM201910375_CR29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nnano.2015.292","volume":"11","author":"PH Lizotte","year":"2015","unstructured":"Lizotte PH, Wen AM, Sheen MR, Fields J, Rojanasopondist P, Steinmetz NF, Fiering S (2015) In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat Nanotechnol 11: 295","journal-title":"Nat Nanotechnol"},{"key":"BFEMMM201910375_CR30","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0035-9203(36)90002-0","volume":"29","author":"W Lloyd","year":"1936","unstructured":"Lloyd W, Theiler M, Ricci NI (1936) Modification of the virulence of yellow fever virus by cultivation in tissues in\u00a0vitro. Trans R Soc Trop Med Hyg 29: 481\u2013529","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"BFEMMM201910375_CR31","first-page":"6017","volume":"54","author":"RM Lorence","year":"1994","unstructured":"Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD, Walter RJ, Peeples ME (1994) Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Can Res 54: 6017\u20136021","journal-title":"Can Res"},{"key":"BFEMMM201910375_CR32","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/annonc\/mdy423","volume":"29","author":"A Marabelle","year":"2018","unstructured":"Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M et\u00a0al (2018) Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT\u2010IT). Ann Oncol 29: 2163\u20132174","journal-title":"Ann Oncol"},{"key":"BFEMMM201910375_CR33","doi-asserted-by":"crossref","first-page":"9197","DOI":"10.1128\/JVI.74.19.9197-9205.2000","volume":"74","author":"A McAllister","year":"2000","unstructured":"McAllister A, Arbetman AE, Mandl S, Pena\u2010Rossi C, Andino R (2000) Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J Virol 74: 9197\u20139205","journal-title":"J Virol"},{"key":"BFEMMM201910375_CR34","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm0697-682","volume":"3","author":"I Melero","year":"1997","unstructured":"Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L (1997) Monoclonal antibodies against the 4\u20101BB T\u2010cell activation molecule eradicate established tumors. Nat Med 3: 682\u2013685","journal-title":"Nat Med"},{"key":"BFEMMM201910375_CR35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2051","volume":"7","author":"I Melero","year":"2007","unstructured":"Melero I, Hervas\u2010Stubbs S, Glennie M, Pardoll DM, Chen L (2007) Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7: 95\u2013106","journal-title":"Nat Rev Cancer"},{"key":"BFEMMM201910375_CR36","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1158\/0008-5472.CAN-13-3356","volume":"75","author":"I Melero","year":"2015","unstructured":"Melero I, Quetglas JI, Reboredo M, Dubrot J, Rodriguez\u2010Madoz JR, Mancheno U, Casales E, Riezu\u2010Boj JI, Ruiz\u2010Guillen M, Ochoa MC et\u00a0al (2015) Strict requirement for vector\u2010induced type I interferon in efficacious antitumor responses to virally encoded IL12. Can Res 75: 497\u2013507","journal-title":"Can Res"},{"key":"BFEMMM201910375_CR37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","volume":"64","author":"TP Monath","year":"2015","unstructured":"Monath TP, Vasconcelos PF (2015) Yellow fever. J Clin Virol 64: 160\u2013173","journal-title":"J Clin Virol"},{"key":"BFEMMM201910375_CR38","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1158\/1078-0432.CCR-13-1189","volume":"19","author":"A Morales\u2010Kastresana","year":"2013","unstructured":"Morales\u2010Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez\u2010Forero I, Labiano S, Hervas\u2010Stubbs S, Sangro B, Ochoa C, Rouzaut A et\u00a0al (2013) Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res 19: 6151\u20136162","journal-title":"Clin Cancer Res"},{"key":"BFEMMM201910375_CR39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1568009617666170222125035","volume":"18","author":"P Msaouel","year":"2018","unstructured":"Msaouel P, Opyrchal M, Dispenzieri A, Peng KW, Federspiel MJ, Russell SJ, Galanis E (2018) Clinical trials with oncolytic measles virus: current status and future prospects. Curr Cancer Drug Targets 18: 177\u2013187","journal-title":"Curr Cancer Drug Targets"},{"key":"BFEMMM201910375_CR40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev-immunol-032713-120204","volume":"34","author":"TL Murphy","year":"2016","unstructured":"Murphy TL, Grajales\u2010Reyes GE, Wu X, Tussiwand R, Briseno CG, Iwata A, Kretzer NM, Durai V, Murphy KM (2016) Transcriptional control of dendritic cell development. Annu Rev Immunol 34: 93\u2013119","journal-title":"Annu Rev Immunol"},{"key":"BFEMMM201910375_CR41","doi-asserted-by":"crossref","first-page":"33165","DOI":"10.18632\/oncotarget.5320","volume":"6","author":"MR Patel","year":"2015","unstructured":"Patel MR, Jacobson BA, Ji Y, Drees J, Tang S, Xiong K, Wang H, Prigge JE, Dash AS, Kratzke AK et\u00a0al (2015) Vesicular stomatitis virus expressing interferon\u2010beta is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non\u2010small cell lung cancer. Oncotarget 6: 33165\u201333177","journal-title":"Oncotarget"},{"key":"BFEMMM201910375_CR42","doi-asserted-by":"crossref","first-page":"e1503032","DOI":"10.1080\/2162402X.2018.1503032","volume":"7","author":"JG Pol","year":"2018","unstructured":"Pol JG, Levesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner JE, Fend L, Bell JC, Mossman KL et\u00a0al (2018) Trial Watch: oncolytic viro\u2010immunotherapy of hematologic and solid tumors. Oncoimmunology 7: e1503032","journal-title":"Oncoimmunology"},{"key":"BFEMMM201910375_CR43","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","volume":"34","author":"I Puzanov","year":"2016","unstructured":"Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J et\u00a0al (2016) Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB\u2010IV melanoma. J Clin Oncol 34: 2619\u20132626","journal-title":"J Clin Oncol"},{"key":"BFEMMM201910375_CR44","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/2326-6066.CIR-14-0216","volume":"3","author":"JI Quetglas","year":"2015","unstructured":"Quetglas JI, Labiano S, Aznar MA, Bolanos E, Azpilikueta A, Rodriguez I, Casales E, Sanchez\u2010Paulete AR, Segura V, Smerdou C et\u00a0al (2015) Virotherapy with a semliki forest virus\u2010based vector encoding IL12\u00a0synergizes with PD\u20101\/PD\u2010L1 blockade. Cancer Immunol Res 3: 449\u2013454","journal-title":"Cancer Immunol Res"},{"key":"BFEMMM201910375_CR45","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/mt.2015.156","volume":"24","author":"K Rajani","year":"2016","unstructured":"Rajani K, Parrish C, Kottke T, Thompson J, Zaidi S, Ilett L, Shim KG, Diaz RM, Pandha H, Harrington K et\u00a0al (2016) Combination therapy with reovirus and anti\u2010PD\u20101 blockade controls tumor growth through innate\u00a0and adaptive immune responses. Mol Ther 24: 166\u2013174","journal-title":"Mol Ther"},{"key":"BFEMMM201910375_CR46","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E et\u00a0al (2017) Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti\u2010PD\u20101 immunotherapy. Cell 170: 1109\u20131119 e10","journal-title":"Cell"},{"key":"BFEMMM201910375_CR47","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359: 1350\u20131355","journal-title":"Science"},{"key":"BFEMMM201910375_CR48","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","volume":"26","author":"JM Ricca","year":"2018","unstructured":"Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L, Merghoub T, Wolchok JD, Zamarin D (2018) Pre\u2010existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy. Mol Ther 26: 1008\u20131019","journal-title":"Mol Ther"},{"key":"BFEMMM201910375_CR49","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, Casanova\u2010Acebes M, Khudoynazarova M, Agudo J, Tung N et\u00a0al (2016) Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD\u2010L1 and BRAF inhibition. Immunity 44: 924\u2013938","journal-title":"Immunity"},{"key":"BFEMMM201910375_CR50","doi-asserted-by":"crossref","first-page":"eaam7577","DOI":"10.1126\/scitranslmed.aam7577","volume":"10","author":"A Samson","year":"2018","unstructured":"Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ et\u00a0al (2018) Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes\u00a0for\u00a0subsequent checkpoint blockade. Sci Transl Med 10: eaam7577","journal-title":"Sci Transl Med"},{"key":"BFEMMM201910375_CR51","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","volume":"6","author":"AR Sanchez\u2010Paulete","year":"2016","unstructured":"Sanchez\u2010Paulete AR, Cueto FJ, Martinez\u2010Lopez M, Labiano S, Morales\u2010Kastresana A, Rodriguez\u2010Ruiz ME, Jure\u2010Kunkel M, Azpilikueta A, Aznar MA, Quetglas JI et\u00a0al (2016) Cancer immunotherapy with immunomodulatory anti\u2010CD137 and anti\u2010PD\u20101 monoclonal antibodies requires BATF3\u2010dependent dendritic cells. Cancer Discov 6: 71\u201379","journal-title":"Cancer Discov"},{"key":"BFEMMM201910375_CR52","doi-asserted-by":"crossref","first-page":"xii44","DOI":"10.1093\/annonc\/mdx237","volume":"28","author":"AR Sanchez\u2010Paulete","year":"2017","unstructured":"Sanchez\u2010Paulete AR, Teijeira A, Cueto FJ, Garasa S, Perez\u2010Gracia JL, Sanchez\u2010Arraez A, Sancho D, Melero I (2017) Antigen cross\u2010presentation and T\u2010cell cross\u2010priming in cancer immunology and immunotherapy. Ann Oncol 28: xii44\u2013xii55","journal-title":"Ann Oncol"},{"key":"BFEMMM201910375_CR53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger S, Dai D, Horton B, Gajewski TF (2017) Tumor\u2010residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31: 711\u2013723 e4","journal-title":"Cancer Cell"},{"key":"BFEMMM201910375_CR54","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.2012.11-0525","volume":"86","author":"RE Thomas","year":"2012","unstructured":"Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T (2012) The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hyg 86: 359\u2013372","journal-title":"Am J Trop Med Hyg"},{"key":"BFEMMM201910375_CR55","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.3390\/v7122938","volume":"7","author":"S Turnbull","year":"2015","unstructured":"Turnbull S, West EJ, Scott KJ, Appleton E, Melcher A, Ralph C (2015) Evidence for oncolytic virotherapy: where have we got to and where are we going? Viruses 7: 6291\u20136312","journal-title":"Viruses"},{"key":"BFEMMM201910375_CR56","unstructured":"Venter EH (2014) The isolation and identification of viruses using embryonated chicken eggs"},{"key":"BFEMMM201910375_CR57","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1073\/pnas.1506357112","volume":"112","author":"B Weigelin","year":"2015","unstructured":"Weigelin B, Bolanos E, Teijeira A, Martinez\u2010Forero I, Labiano S, Azpilikueta A, Morales\u2010Kastresana A, Quetglas JI, Wagena E, Sanchez\u2010Paulete AR et\u00a0al (2015) Focusing and sustaining the antitumor CTL effector killer response by agonist anti\u2010CD137 mAb. Proc Natl Acad Sci USA 112: 7551\u20137556","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM201910375_CR58","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15: 486\u2013499","journal-title":"Nat Rev Immunol"},{"key":"BFEMMM201910375_CR59","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1084\/jem.20160485","volume":"214","author":"JB Williams","year":"2017","unstructured":"Williams JB, Horton BL, Zheng Y, Duan Y, Powell JD, Gajewski TF (2017) The EGR2 targets LAG\u20103 and 4\u20101BB describe and regulate dysfunctional antigen\u2010specific CD8+ T cells in the tumor microenvironment. J Exp Med 214: 381\u2013400","journal-title":"J Exp Med"},{"key":"BFEMMM201910375_CR60","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1016\/j.vaccine.2017.06.087","volume":"35","author":"World Health Organization","year":"2017","unstructured":"World Health Organization (2017) WHO position on the use of fractional\u00a0doses \u2010 June 2017, addendum to vaccines and vaccination against yellow fever WHO: position paper \u2010 June 2013. Vaccine 35: 5751\u20135752","journal-title":"Vaccine"},{"key":"BFEMMM201910375_CR61","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP (2014) Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6: 226ra32","journal-title":"Sci Transl Med"},{"key":"BFEMMM201910375_CR62","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/mt.2010.313","volume":"19","author":"L Zhang","year":"2011","unstructured":"Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, Morgan RA (2011) Improving adoptive T cell therapy by targeting and controlling IL\u201012 expression to the tumor environment. Mol Ther 19: 751\u2013759","journal-title":"Mol Ther"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.201910375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.15252\/emmm.201910375","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.15252\/emmm.201910375\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.15252\/emmm.201910375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.201910375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:27:06Z","timestamp":1779085626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.15252\/emmm.201910375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,9]]}},"alternative-id":["BFEMMM201910375"],"URL":"https:\/\/doi.org\/10.15252\/emmm.201910375","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,19]]},"assertion":[{"value":"25 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"IM reports receiving commercial research grants from BMS, Alligator, and\u00a0ROCHE and serves as a consultant\/advisory board member for BMS, Merck\u2010Serono, Roche\u2010Genentech, Genmab, Incyte, Bioncotech, Tusk, Molecular partners F\u2010STAR, Alligator, Bayer, Numab, Immunedesign, and AstraZeneca.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"EMMM201910375"}}